The specter of generic competition has long loomed above copyright’s famous drug, Sildenafil, raising questions about the future of connected drug ventures. While initial periods saw significant profits, the exclusivity end has allowed the door for discounted alternatives, possibly reducing profitability and presenting a real risk for shareholder